tetano
Editor, Senior Moderator
J Thromb Haemost. 2020 Apr 17. doi: 10.1111/jth.14848. [Epub ahead of print]
Thrombocytopenia and Its Association with Mortality in Patients with COVID-19.
Yang X[SUP]1,[/SUP][SUP]2[/SUP], Yang Q[SUP]2[/SUP], Wang Y[SUP]1[/SUP], Wu Y[SUP]1[/SUP], Xu J[SUP]1[/SUP], Yu Y[SUP]1[/SUP], Shang Y[SUP]1,[/SUP][SUP]2[/SUP].
Author information
Abstract
BACKGROUND:
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which causes novel coronavirus disease 2019 (COVID-19), is spreading rapidly around the world. Thrombocytopenia in patients with COVID-19 has not been fully studied.
OBJECTIVE:
To describe thrombocytopenia in patients with COVID-19.
METHODS:
For each of 1476 consecutive patients with COVID-19 from Jinyintan Hospital, Wuhan, China, nadir platelet count during hospitalization was retrospectively collected and categorized into (0, 50], (50, 100], (100 - 150] or (150 - ) group after taking the unit (? 10[SUP]9/L[/SUP] ) away from the report of nadir platelet count. Nadir platelet counts and in-hospital mortality were analyzed.
RESULTS:
Among all patients, 238 (16.1%) patients deceased and 306 (20.7%) had thrombocytopenia. Compared with survivors, non-survivors were older, were more likely to have thrombocytopenia and had lower nadir platelet counts. The in-hospital mortality was 92.1%, 61.2%, 17.5% and 4.7% for (0, 50], (50, 100], (100 - 150] and (150 - ) group, respectively. With (150 - ) as the reference, nadir platelet counts of (100 - 150], (50, 100] and (0, 50] group had a relative risk of 3.42 (95% CI 2.36 - 4.96), 9.99 (95% CI 7.16 - 13.94) and 13.68 (95% CI 9.89 - 18.92), respectively.
CONCLUSIONS:
Thrombocytopenia is common in patients with COVID-19, and it is associated with increased risk of in-hospital mortality. The lower the platelet count is, the higher the mortality becomes.
This article is protected by copyright. All rights reserved.
KEYWORDS:
COVID-19; SARS-CoV-2; generalized linear model; mortality; thrombocytopenia
PMID:32302435DOI:10.1111/jth.14848
Thrombocytopenia and Its Association with Mortality in Patients with COVID-19.
Yang X[SUP]1,[/SUP][SUP]2[/SUP], Yang Q[SUP]2[/SUP], Wang Y[SUP]1[/SUP], Wu Y[SUP]1[/SUP], Xu J[SUP]1[/SUP], Yu Y[SUP]1[/SUP], Shang Y[SUP]1,[/SUP][SUP]2[/SUP].
Author information
Abstract
BACKGROUND:
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which causes novel coronavirus disease 2019 (COVID-19), is spreading rapidly around the world. Thrombocytopenia in patients with COVID-19 has not been fully studied.
OBJECTIVE:
To describe thrombocytopenia in patients with COVID-19.
METHODS:
For each of 1476 consecutive patients with COVID-19 from Jinyintan Hospital, Wuhan, China, nadir platelet count during hospitalization was retrospectively collected and categorized into (0, 50], (50, 100], (100 - 150] or (150 - ) group after taking the unit (? 10[SUP]9/L[/SUP] ) away from the report of nadir platelet count. Nadir platelet counts and in-hospital mortality were analyzed.
RESULTS:
Among all patients, 238 (16.1%) patients deceased and 306 (20.7%) had thrombocytopenia. Compared with survivors, non-survivors were older, were more likely to have thrombocytopenia and had lower nadir platelet counts. The in-hospital mortality was 92.1%, 61.2%, 17.5% and 4.7% for (0, 50], (50, 100], (100 - 150] and (150 - ) group, respectively. With (150 - ) as the reference, nadir platelet counts of (100 - 150], (50, 100] and (0, 50] group had a relative risk of 3.42 (95% CI 2.36 - 4.96), 9.99 (95% CI 7.16 - 13.94) and 13.68 (95% CI 9.89 - 18.92), respectively.
CONCLUSIONS:
Thrombocytopenia is common in patients with COVID-19, and it is associated with increased risk of in-hospital mortality. The lower the platelet count is, the higher the mortality becomes.
This article is protected by copyright. All rights reserved.
KEYWORDS:
COVID-19; SARS-CoV-2; generalized linear model; mortality; thrombocytopenia
PMID:32302435DOI:10.1111/jth.14848